SCHEMBL524232

SCHEMBL524232

Nc1cccc(C(=O)O)c1S(=O)(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.55
ALOX15 P16050 2/20 0.50
CASP7 P55210 2/20 0.46
G6PD P11413 1/20 0.46
CASP6 P55212 1/20 0.46
ALDH1A1 P00352 2/20 0.43
TTR P02766 1/20 0.43
CYP2D6 P10635 1/20 0.42
CDC25B P30305 1/20 0.42
MAPT P10636 2/20 0.41
GAA P10253 1/20 0.41
HSD17B10 Q99714 2/20 0.41
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 1/20 0.41
CASP3 P42574 1/20 0.41
RAB9A P51151 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
IDO1 P14902 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL10638262 0.86 ALOX15 (0.59) MMP2ALOX15CASP7G6PDCASP6
SCHEMBL65889 0.86 ALOX15 (0.59) MMP2ALOX15CASP7G6PDCASP6
SCHEMBL15641523 0.85 TTR (0.43) MMP2ALDH1A1TTRMAPTGAA
SCHEMBL28069384 0.85 MMP2 (0.55) MMP2ALOX15CASP7G6PDCASP6
SCHEMBL812165 0.84 ALOX15 (0.57) MMP2ALOX15CASP7G6PDCASP6
SCHEMBL3781304 0.84 ALOX15 (0.57) MMP2ALOX15CASP7G6PDCASP6
Phosphine SCHEMBL3820807 0.84 ALOX15 (0.57) MMP2ALOX15CASP7G6PDCASP6
SCHEMBL20471934 0.84 ALOX15 (0.57) MMP2ALOX15CASP7G6PDCASP6
Phosphine SCHEMBL3135561 0.84 ALOX15 (0.57) MMP2ALOX15CASP7G6PDCASP6
SCHEMBL143947 0.84 ALOX15 (0.57) MMP2ALOX15CASP7G6PDCASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2024-04-04 US disclosed
US-11787802-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2022-09-15 US disclosed
US-11254672-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2022-02-22 US disclosed
CN-215123347-U Automatic metal wire code manufacturing device 浙江海洋大学 2021-12-14 CN disclosed
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2020-07-02 US disclosed
US-8697739-B2 Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof NOVARTIS AG (CH) 2014-04-15 US disclosed
WO-2012159116-A2 FLUORESCENT PROBES FOR MONITORING VOLTAGE BY PHOTO-INDUCED ELECTRON TRANSFER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-11-22 WO disclosed
US-20120028969-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2012-02-02 US disclosed
US-20110294853-A1 Bis Aromatic Compounds for Use in the Treatment of Inflammation BIOLIPOX AB (SE) 2011-12-01 US disclosed
US-20100144872-A1 New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation BIOLIPOX AB 2010-06-10 US disclosed
US-20100124713-A1 TONERS INCLUDING CARBON NANOTUBES DISPERSED IN A POLYMER MATRIX XEROX CORPORATION (US) 2010-05-20 US disclosed
US-20100122642-A1 INKS INCLUDING CARBON NANOTUBES DISPERSED IN A POLYMER MATRIX XEROX CORPORATION (US) 2010-05-20 US disclosed
EP-2187266-A1 Toners including carbon nanotubes dispersed in a polymer matrix Xerox Corporation (US) 2010-05-19 EP disclosed
US-4642240-A LOW CALORIE SWEETENERS GENERAL FOODS CORPORATION (US) 1987-02-10 US disclosed
US-4001205-A WATER-SOLUBLE, FIBER-REACTIVE PHENYLAZODIHYDROXY, METHYL, CYANOPYRIDINE DYESTUFFS CIBA-GEIGY AG (CH) 1977-01-04 US disclosed
US-3956263-A 4-Methyl-2,6-dihydroxy-3-cyanopyridine containing dyestuffs CIBA-GEIGY AG (CH) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 MMP2 3896/4885ALOX15 4668/4885CASP7 3493/4885
US-20120028969-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF ACACA, ACACB, COASY MMP2 1751/4885ALOX15 1133/4885CASP7 4321/4885
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 MMP2 3896/4885ALOX15 4668/4885CASP7 3493/4885
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 MMP2 3896/4885ALOX15 4668/4885CASP7 3493/4885
US-20110294853-A1 Bis Aromatic Compounds for Use in the Treatment of Inflammation LTC4S, LTB4R2, LTB4R MMP2 2257/4885ALOX15 10/4885CASP7 1657/4885
US-11787802-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 MMP2 3896/4885ALOX15 4668/4885CASP7 3493/4885
US-11254672-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 MMP2 3896/4885ALOX15 4668/4885CASP7 3493/4885
US-20100144872-A1 New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation LTC4S, LTB4R2, LTB4R MMP2 1220/4885ALOX15 18/4885CASP7 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.